BioVie Inc. announced the appointment of Dr. Patrick Yeramian as consultant Medical Director to guide the clinical development program for the company's new drug candidate, BIV201. Prior to joining the BioVie team, Dr. Yeramian worked with the company's regulatory expert, Stacy Suberg. Dr. Yeramian brings three decades of experience in research and drug and medical device development to BioVie's management team. He has served as a medical director for multiple organizations including Searle Pharmaceuticals (now Pfizer), the Vaccine and Gene Therapy Institute of Florida, and TapImmune Inc.